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INTRODUCTION
The American Thoracic Society/European Respiratory Society 
(ATS/ERS) statement on asthma control defines asthma control 
as ‘the extent to which manifestations of asthma are reduced or 
removed by treatment’ .
1 This definition is further clarified into 
two components: current clinical asthma control and future 
risk. The level of clinical asthma control is defined according to 
symptoms, and the degree to which asthma impairs the indi-
vidual’s day-to-day activities and quality of life. Measures that 
are commonly used to quantify asthma symptoms in primary 
care are daytime and night-time symptoms, reduced activities, 
level of short acting β2 agonist reliever usage and impaired lung 
function. The Global Initiative for Asthma (GINA) recommends 
using a composite measure comprising all of these 5 measures 
to enable stratification of disease control into: ‘controlled’ , ‘part-
ly controlled’ or ‘uncontrolled’ .
2 
While these measures give an indication of the current level of 
disease control, asthma control should also reflect the minimi-
sation of future risk of exacerbation or of disease progression. 
An exacerbation is defined in the ATS/ERS statement on asth-
ma control as an event that requires urgent intervention,
1 and is 
usually defined by the prescription of an acute course of oral 
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corticosteroids (OCS), hospitalisation or emergency room visit 
due to asthma. Exacerbations are the time of greatest risk to a 
patient, result in impaired quality of life and are a significant 
drain on healthcare budgets. Understanding factors predictive 
of exacerbation is therefore of great importance. Using a pro-
spective survey study design, Guilbert et al.
3 have recently re-
ported that asthma that is not well controlled is associated with 
higher unscheduled healthcare resource use. In a retrospective 
analysis of the Gaining Optimal Asthma Control (GOAL) study 
database, Bateman et al.
4 have also demonstrated that the de-
gree of variability in asthma control is also associated with un-
scheduled healthcare resource use. Indeed, they showed that 
variability in asthma control is predictive of the use of unsched-
uled healthcare resource use, with higher variability in asthma 
control associated with a higher likelihood of unscheduled 
healthcare resource use.
4 Bateman and colleagues
5 have further 
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reported that current asthma control is a predictor of future in-
stability in asthma control and asthma exacerbations.
Despite national guidelines, poor asthma control remains 
highly prevalent. A recent pan-European cross-sectional survey 
found that in 2008, 57% of adult asthmatics had ‘not well con-
trolled’ asthma on a validated symptom instrument, with no 
improvement since 2006.
6 In a study conducted across 36 UK 
GP practices, Price et al.
7 demonstrated that 36.5% of patients 
had an Asthma Control Questionnaire (ACQ) score of higher 
than 1.5, indicative of poor asthma control, and 14.2% had re-
ceived one or more acute courses of oral corticosteroids in the 
previous 12 months. In a study using the Netherlands based 
PHARMO Record Linkage System, Breekveldt-Postma observed, 
in a study limited to patients with severe asthma, that 17% of 
patients showed lack of asthma control with costs related to 
asthma hospitalisations and excess therapies exceeding €10,000 
per patient per year.
8 In a recent US study Guilbert et al.
3 report-
ed that compared to adult asthmatics with well controlled asth-
ma, over a 9 month period adults with baseline asthma that 
was not well controlled had significantly lower health related 
quality of life, were at three fold greater risk of an asthma relat-
ed doctor visit and had a 10 fold greater risk of attending the 
emergency department because of asthma.
International (GINA, ATS and ERS) guidelines recommend 
that patients should be stepped up or down on a treatment al-
gorithm to gain control and afford minimal symptoms and re-
liever usage.
2,9-11 Several studies have explored the relationship 
between inhaled corticosteroids (ICS), long acting beta2 ago-
nists (LABA) and asthma exacerbations. In the landmark FAC-
ET randomised clinical trial, Pauwels and colleagues reported 
that the higher dose of budesonide (800 µg per day) resulted in 
a significantly (P=0.03) greater reduction in severe exacerba-
tions than those receiving the LABA formoterol in addition to 
low dose budesonide (200 µg per day; 49% vs. 26% P=0.03). In 
line with its bronchodilator activity, significantly more optimal-
ly-controlled days, less day-time rescue medication use and 
night-time symptoms were observed when formoterol was 
added to budesonide (low or high dose). Consistent with the 
results of the FACET study, in a retrospective cohort study using 
the General Practice Research Database (GPRD), Thomas et 
al.
12 compared the outcome of patients receiving LABA on a 
background of ICS compared to increasing the dose of ICS. Af-
ter controlling for baseline differences and adjusting for con-
founders, patients receiving LABA were more likely to have im-
proved symptomatic control and reduced bronchodilator us-
age but were found to be at higher risk of severe exacerbations 
and hospitalisations than those receiving an increase in ICS 
dose. This indicates that while bronchodilator therapy improved 
symptomatic control, reduction in exacerbation risk may re-
quire effective control of inflammation. 
An ATS/ERS Task Force on outcome measures in asthma
10 
and GINA
11 have indicated that the objective of asthma man-
agement should be to 1) achieve current asthma control as de-
fined by symptoms, reliever usage, activity and lung function; 
and 2) reduce future risk of exacerbations, loss of lung function 
or adverse medication effects. Reducing future risk of exacerba-
tions is dependent upon the identification of predictive factors, 
and determining their relative influence on the future risk of ex-
acerbations. 
Here we discuss the literature on the prediction of exacerba-
tions in conjunction with factors associated with difficult to 
treat asthma and frequent exacerbations, and discuss how they 
could be applied to the routine management of patients in pri-
mary care. Summaries of the factors associated with worst asth-
ma control and future risk of poor asthma control are shown in 
Tables 1 and 2, respectively. 
Factors associated with asthma exacerbations
Previous exacerbations
An acute asthma exacerbation (AAE) is usually defined as a 
worsening of asthma requiring a short course of OCS, visit to an 
emergency department or hospitalisation for asthma. Patients 
with a history of past asthma exacerbations have been reported 
to be at an increased risk of asthma exacerbations. Peters et al.
13 
reported that a history of an AAE is predictive of future AAE. Us-
ing GPRD to compare patients with or without hospitalisations 
in the outcome year, Price et al.
14 reported that adults who had 
received 1 or more courses of oral corticosteroids in the base-
line year, were 3 times more likely to have an asthma related 
hospitalisation during the following (outcome) year. The re-
quirement for a short course of OCS has been shown to be pre-
dictive of future OCS need.
8,15,16 Using The Epidemiology and 
Natural History of Asthma: Outcomes and Treatment Regi-
mens (TENOR) database,
17 Miller et al.
18 reported that patients 
who have had a recent severe exacerbation requiring hospitali-
sation or an emergency room visit in the prior three months 
were at a 3-fold greater risk of future exacerbation compared to 
patients who have not had a recent severe exacerbation.
Asthma control
Asthma control is most often assessed through patient report-
ed symptoms, reliever usage and, in some cases, including the 
GINA guidelines, lung function.
2,13,19-21 Bateman et al.,
5 in a ret-
rospective analysis of five budesonide/formoterol maintenance 
and reliever therapy studies, reported that current asthma con-
trol in a given week, as assessed by the GINA –defined Asthma 
Control status,
11 can be used to predict the level of asthma con-
trol in the following week. They reported that the higher the lev-
el of poor asthma control in the index week, the greater the esti-
mated probability of having an exacerbation in the following 
week. Bateman et al.
5 also reported that poor asthma control at 
randomisation, assessed using the ACQ, is predictive of future 
risk of exacerbation. Poor asthma control (defined as 3-4 con-
trol problems on the Asthma Therapy Assessment Question-Control and Future Risk in Asthma Management
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naire [ATAQ]) has been associated with increased risk of severe 
asthma related events,
22 defined as oral steroid bursts, emer-
gency room visits or a hospital admission. Poor asthma control 
has also been associated with increased acute-health care utili-
sation,
13 although Peters et al.
13 also reported that asthma con-
trol was not as strong a predictor of acute-health care utilisation 
as healthcare utilisation data (asthma related hospital admis-
sion and emergency room attendance). Consistently very poor-
ly controlled asthma, defined by the impairment domain (in-
cluding spirometry) of the National Heart Lung and Blood In-
stitute (NHLBI) guidelines,
23,24 compared to variably controlled 
asthma, has also been shown to be associated with a 6-fold in-
creased risk of asthma exacerbation in children and a 3.2 fold 
increased risk of asthma exacerbation in adolescents or adults.
25 
The concept of sub-acute lack of asthma control (SALAC) has 
been utilised in 2 studies. Using administrative claims databas-
es (Patient Centric Database [PharMetrics/IMS Health Inc., 
Watertown, MA, USA] and HealthCore Integrated Research Da-
tabase [HealthCore Inc., Wilmington, DE, USA]), and defining 
SALAC as requiring more than 5 prescriptions of reliever thera-
py in a year or having attended their primary care physician on 
more than 4 occasions in a year, O’Connor et al.
16 and Stephen-
son et al.
15 reported SALAC as being predictive of future exacer-
bation. However, due to limitations in the data available, no fur-
ther analyses of additional contributory predictive factors was 
possible. 
Inhaler technique
The correct use of inhaler devices, is essential for optimal drug 
delivery and clinical benefit.
26 However, poor inhaler technique 
remains common
26 and has been associated with increased un-
scheduled health-care resource use and poor asthma control.
27 
Despite this, inhaler technique status has not been included in 
most analyses aimed at identifying risk factors predictive of fu-
ture exacerbations. 
Lower respiratory tract infections and recurrent respiratory 
infections
There is a growing body of evidence concerning the role of 
bacterial infections in asthma.
28 Lower respiratory tract infec-
tions requiring antibiotics are not usually included in the defi-
nition of an exacerbation however. Although a visit to a primary 
care provider resulting in a prescription of antibiotics would be 
captured by measuring attendances at primary care providers, 
the attendance would not indicate the severity of an exacerba-
tion as would be indicated by an antibiotic prescription. Using 
the GPRD, Price et al.
29 reported in a matched analysis that 19% 
of patients with mild to moderate asthma had received antibi-
otics for a lower respiratory infection in the baseline year, com-
pared to 16% receiving ≥1 acute courses of oral corticosteroids. 
Research is required to determine the value of including lower 
respiratory tract infections in the definition of an exacerbation. 
Table 1.  Summary of factors associated with worst asthma control
Factor  Study type Patient group
Measure of  
Asthma Control Results  P Reference
Body Mass Index (BMI)
Interview and  
questionnaire study
Adults with 
moderate to severe  
asthma
ACQ  BMI<25: 1.63±0.09 
BMI≥25<30: 1.6±0.08 
BMI≥30: 1.93±0.1
F=5.96
<0.01
Lavoie et al.
58
AQLQ BMI<25: 5.18±0.11 
BMI≥25<30: 5.17±0.11 
BMI≥30: 4.84±0.13
F=6.30
<0.01
Lavoie et al.
58
Increase in weight
Historical Cohort  
Study (TENOR)
Adults with severe  
or difficult to treat
ATAQ 
Acute Oral  
Steroids 
Adjusted odds ratio:
1.22 (95%CI: 1.01-1.49)
1.31 (95%CI: 1.04-1.66)
0.04
0.02
Haselkorn et al.
57
Gender ATAQ;  
Exacerbations
Female worse <0.05;
<0.05
Haselkorn et al.
57
Race ATAQ; 
Exacerbations
Being black rather than  
white
<0.05;
<0.05
Haselkorn et al.
57
Employment ATAQ; 
Exacerbations
Being disabled rather  
than full time employed
<0.05;
<0.05
Haselkorn et al.
57
Acute Course OCS in  
previous year
Acute Course  
OCS
Acute OCS in baseline  
year rather than no OCS
0.05 Haselkorn et al.
57
Discontinuation of  
ICS (first 3 months)
Nested Case-Control  
study using Historical  
Cohort (Saskatchewan 
Health databases)
Age 5 to 44 years
Death Adjusted rate ratio
4.6 (95%CI: 1.1-19.1)
<0.05 Suissa et al.
61
Irregular use of ICS   Hospitalisation Adjusted rate ratio
1.73 (95%CI: 1.41-2.11)
<0.05 Suissa et al.
30
TENOR, The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens; ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life 
Questionnaire; ATAQ, Asthma Therapy Assessment Questionnaire; OCS, oral corticosteroids; ICS, inhaled corticosteroids.Sims et al.
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Table 2.  Summary of factors associated with future risk of poor asthma control
Factor  Study type Patient group Predictive of: Odds ratio  P Reference
Exacerbations* Historical Cohort Study  
(Health Care Plan: Pharmetrics)
Aged ≥12 yr  Exacerbations* only
Exacerbations AND 
≥6 SABA
†
2.503 (2.176-2.879)
3.394 (3.009-3.827)
<0.0001
<0.0001
O’Connor et al.
16
Hospitalisation Questionnaire & Historical Cohort 
Study (Health Care Plan: K-P)
Adults High SABA usage  1.4 (1.2-1.7)  0.0004 Schatz et al.
52
Oral corticosteroid use  Historical Cohort Study (GPRD) Adults  Hospitalisation 3.01 (1.90-4.78) <0.0001 Price et al.
14
Historical Cohort Study (GPRD) Children 6-15 yr Hospitalisation 2.24 (1.08-4.67) 0.0314 Thomas et al.
35
Questionnaire & Historical Cohort 
Study (Health Care Plan: K-P)
Adults High SABA usage 1.9 (1.4-2.5) for >2 
acute courses OCS  
in baseline year
<0.0001 Schatz et al.
52
Variability in  
asthma control
Retrospective analysis of  
Randomised Controlled Trial (GOAL)
Aged ≥12 yr Unscheduled health-
care resource use
1.06 (1.05-1.07) <0.001 Bateman et al.
4 
Poor asthma  
control 
(Asthma Control 
Questionnaire ≥1.5)
Retrospective analysis of 5 
budesonide/formoterol  
maintenance and reliever  
therapy studies
Aged 4 to 89 yr Exacerbations* 
(events/patient/year)
ACQ ≥1.5: 0.36 
(95% CI:0.09-0.20)
ACQ <0.50: 0.13 
(95% CI:0.09-0.20) 
<0.001 Bateman et al.
5
Female gender Historical Cohort Study (GPRD) Adults Hospitalisation 1.56 (1.09-2.22)  0.0155 Price et al.
14
Historical Cohort Study  
(Health Care Plan: Pharmetrics)
Aged ≥12 yr  Exacerbations* 1.329 (1.224-1.443) <0.0001 O’Connor et al.
16
Male gender Questionnaire & Historical Cohort 
Study (Health Care Plan: K-P)
Adults High SABA usage  1.5 (1.3-1.8)  <0.0001 Schatz et al.
52
Age Cross-sectional survey Adults ACQ≥1.5 1.01 (1.01-1.02) <0.001 Clatworthy et al.
31
Age 12 to 17 yr vs.  
45-54 yr or vs. ≥55 yr 
Historical Cohort Study  
(Health Care Plan: Pharmetrics)
Aged ≥12 yr  Exacerbations* 0.836 (0.742-0.942) 
0.841 (0.727-0.973)
0.0032
0.0199
O’Connor et al.
16
Allergic rhinitis Historical Cohort Study (GPRD) Adults Hospitalisation 1.52 (1.03-2.24) 0.0365 Price et al.
14
Children 6-15 yr Hospitalisation 2.34 (1.41-3.91) <0.0011 Thomas et al.
35
Mild rhinitis Cross-sectional survey Adults  ACQ≥1.5 2.09 (1.72-2.54) <0.001 Clatworthy et al.
31 
Severe rhinitis 4.62 (3.71-5.77) <0.001
SABA prescriptions Historical Cohort Study (GPRD) Adults Hospitalisation 1.15 (1.10-1.21) <0.0001 Price et al.
14
Children 6-15 yr Hospitalisation 1.25 (1.13-1.39) <0.0001 Thomas et al.
35
≥6 SABA 
prescriptions/yr 
+ >4 physician 
visits in the yr
Historical Cohort Study  
(Health Care Plan: Pharmetrics)
Aged ≥12 yr  Exacerbations* 1.277 (1.166-1.399) <0.0001 O’Connor et al.
16
Historical Cohort Study (HealthCore 
Integrated : Research Database)
Aged ≥6-64 yr Exacerbations* 1.601 (1.514-1.692) <0.001 Stephenson et al.
15 
≥6 SABA 
prescriptions/yr
Historical Cohort Study (HealthCore 
Integrated : Research Database)
Aged ≥6-64 yr Exacerbations* 1.854 (1.719-2.000) <0.001 Stephenson et al.
15
>4 physician visits
in the yr
Aged ≥6-64 yr Exacerbations* 1.340 (1.249-1.438) <0.001 Stephenson et al.
15
Low dose ICS Historical Cohort Study (GPRD) Children 6-15 yr Hospitalisation 1.81 (1.05-3.14) 0.0334 Thomas et al.
35
Medium dose ICS Adults 1.76 (1.13-2.74) 0.0119 Price et al.
14
High dose ICS  
≥800 µg/day
Adults 2.26 (1.04-4.94) 0.0408 Price et al.
14
Children 6-15 yr 5.60 (2.11-14.88) 0.0005 Thomas et al.
35
Low adherence Cross-sectional survey Adults ACQ≥1.5 1.35 (1.18-1.55) <0.001 Clatworthy et al.
31
Weight gain  
(≥5 lb)
Historical Cohort Study (TENOR) Severe or difficult  
to treat adults
Acute course OCS 1.31 (1.04-1.66) <0.02 Haselkorn et al.
57
Active smoking Cross-sectional survey Adults ACQ≥1.5 4.33 (3.58-5.23) <0.001 Clatworthy et al.
31
Questionnaire & Historical Cohort 
Study (Health Care Plan: K-P)
Adults High SABA usage  2.2 (1.7-3.0)  <0.0001 Schatz et al.
52
Past smoking history Cross-sectional survey Adults ACQ≥1.5 1.59 (1.36-1.87) <0.001 Clatworthy et al.
31
*Acute course of OCS OR emergency room attendance for asthma OR hospitalisation for asthma. 
†≥6 SABA prescriptions/year AND/OR >4 physician visits in the year.
GPRD, General Practice Research Database; SABA, Short acting beta2 agonist; ICS, Inhaled corticosteroid; KP, Kaiser-Permanente Medical Care Program; GOAL, 
Gaining Optimal Asthma Control; TENOR, The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens; ACQ, Asthma Control Questionnaire.Control and Future Risk in Asthma Management
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Adherence to therapy
Good adherence to asthma therapy is essential for maximal 
therapeutic benefit and avoidance of exacerbations. Regular 
use of low-dose inhaled corticosteroids has been shown to re-
duce the risk of death and hospitalisations. Using the Saskatch-
ewan Health databases (Government of Saskatchewan, Sas-
katchewan, Canada) and a nested case-control study design, 
Suissa et al.
30 reported the mean number of canisters of low 
dose inhaled corticosteroids used in the year prior to date of 
death (or index date) was 1.18 in patients who had died due to 
asthma compared to 1.57 canisters in the matched control 
group, and that the rate of death decreased by 21% with every 
one additional canister of ICS used in the year prior to death 
(rate ratio: 0.79; 95% CI: 0.65 to 0.97). Exploring death rates fol-
lowing discontinuation of ICS, Suissa et al.
30 reported a four-
fold increase in the rate of death in the three months immedi-
ately following discontinuation of ICS compared to those that 
had continued their ICS. In terms of hospitalisations, in a fur-
ther analysis of the same database, Suissa et al.
30 reported that 
in the 12 months following initiation of ICS, irregular use of ICS 
was associated with a 73% increase in the rate of hospitalisa-
tions, compared to those who took their ICS regularly. Regular 
use of ICS over at least a 4 year period further reduced the rate 
of hospital admissions by 31% compared to those who used 
their ICS irregularly or not all (rate ratio: 0.69; 95% CI: 0.57- 
0.83). Bateman et al.
4 reported that once control of asthma is 
achieved, control is more likely to be maintained where adher-
ence to therapy is good. The inclusion of measures of adher-
ence to therapy in studies evaluating factors predictive of asth-
ma exacerbations has been variable. Haselkorn et al.
25 utilised 
patient reported medication compliance, although this was not 
validated with administrative claims data. In a questionnaire 
study, Clatworthy et al.
31 reported that poor asthma control was 
associated with self-reported low medication adherence.
Allergic rhinitis and allergies
The link between rhinitis and asthma is well recognised
32 with 
60% of asthmatics having concomitant allergic rhinitis, and 20-
30% of people with rhinitis having concomitant asthma.
33 Co-
existing rhinitis and asthma can impact significantly on patient 
quality of life and health care costs.
34 Using the GPRD database, 
Price et al.
14 reported that adults with concomitant allergic rhi-
nitis and asthma experienced significantly more GP visits, more 
asthma-related hospitalisations and higher asthma related 
drug costs than patients with asthma alone. Furthermore, they 
reported that patients with concomitant allergic rhinitis were 
1.52 fold more likely to have an asthma-related hospitalisation 
than those with asthma alone.
14 In children with asthma aged 
6-15 years, concomitant allergic rhinitis increased the likeli-
hood of a hospitalisation for asthma 2.34 fold to that of a child 
with asthma alone.
35 In agreement with the adult study, com-
pared to children with asthma alone, those with asthma and 
concomitant allergic rhinitis had a higher number of GP visits 
and higher asthma related drug costs. Treatment of allergic rhi-
nitis in patients with concomitant asthma has also been shown 
to improve both asthma and rhinitis control. In patients with 
concomitant asthma, after adjusting for baseline differences, 
treatment of allergic rhinitis using the nasal corticosteroid mo-
metasone, were found to have significant improvements in 
both rhinitis control and asthma control compared to matched 
parents receiving oral antihistamines, although the authors 
were unable to identify the variable responsible for driving the 
improvement in asthma control.
36 
Significant untreated rhinitis has been significantly associated 
with poor asthma control.
34 Conversely, Breekveldt-Postma et 
al.
8 reported that treatment of allergic rhinitis with nasal prepa-
rations (corticosteroids or anti-allergic compounds) was not 
significantly associated with uncontrolled asthma in patients 
with severe asthma, suggesting that active treatment of rhinitis 
facilitates improved asthma control. Comparing patients with 
continued very poorly controlled asthma to those who had an 
improvement during the study, Haselkorn et al.
25 reported no 
difference in the proportion of patients with a history of allergic 
rhinitis at baseline. However it was not reported whether pa-
tients were receiving nasal preparations for allergic rhinitis or 
the level of symptoms experienced. In a separate study, Hasel-
korn et al.
37 identified predictors of severe exacerbations in chil-
dren. They reported that patients with 3 to 4 allergic triggers 
(from pollen, dust, pets and mold) were at 2 fold higher risk of 
future asthma exacerbation compared to those who with no al-
lergic triggers. In a questionnaire study, Clatworthy et al.
31 re-
ported that those with self reported rhinitis (severe or mild) 
were more likely to exhibit poor asthma control dependant on 
the severity of the rhinitis.
Gastro-oesophageal reflux disease
A recent systematic review reported an estimated prevalence 
of GORD symptom ranging from 30-90% in asthmatics com-
pared to 10-20% in the general population. People with asthma 
had 5 times the risk of having GORD symptoms, and those with 
GORD had double the risk of asthma.
38 Despite this high fre-
quency, a history of symptoms or treatment of GORD has not 
been included in most analyses aimed at identifying risk factors 
predictive of future asthma exacerbations. Using the TENOR 
study database Chen et al.
39 reported that the presence of 1 or 
more major co-morbidities was a significant independent pre-
dictor of reduced general health status (using EQ-5D), but not 
of asthma specific quality of life (assessed using Mini-AQLQ), 
although they did not define the co-morbidities included. A 
further analysis of the TENOR study database limited the major 
co-morbidities included to chronic obstructive pulmonary dis-
ease, bronchitis and emphysema.
25Sims et al.
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Psychological dysfunction
There is considerable literature on the relationship between 
asthma and psychological dysfunction.
40 Although anxiety is a 
normal response to asthma symptoms, excessive anxiety may 
lead to hyperventilation and subsequently cause airways cool-
ing and bronchoconstriction.
41 Cross-sectional surveys have 
shown that, independently of objective asthma severity and 
other confounding factors, anxiety and depression influences 
symptomatic control and asthma related health status.
42,43 Fear 
of the physical symptoms of uncontrolled asthma has been 
suggested to be linked to poor asthma control. In a recent study 
of anxiety sensitivity in asthma control, McLeish et al.
44 report-
ed that the physical concern domain of the Anxiety Sensitivity 
Index-3 was significantly negatively associated with asthma 
control as assessed by the Asthma Control Test. Worse asthma 
control, in terms of higher asthma hospitalisation rates,
45-47 
higher asthma related mortality
48 as well as less successful asth-
ma emergency treatment
47 have been associated with asthmat-
ic patients with psychological dysfunction compared to those 
with asthma alone. In patients with severe asthma, ten Brinke 
and colleagues reported higher asthma related health care utili-
sation in patients with psychological dysfunction.
49 In a separate 
study, ten Brinke et al.
50 reported no difference in the psycho-
logical characteristics of patients with mild or severe asthma, 
but that com  pared to patients with mild asthma those with se-
vere asthma were more likely to lack trust (or had a lower level 
of trust) in their asthma physician and asthma medication.
Smoking 
The probability of having poorly controlled asthma has been 
shown to be 2.7 fold greater in asthmatics who are active smok-
ers compared to non-smokers and 1.27 fold greater in ex-smok-
ers compared to non-smokers.
51 In agreement, Schatz et al.
52 re-
ported that active smokers were more likely to have poor asth-
ma control, based on SABA canister dispensing, compared to 
non or ex-smokers. Haselkorn et al.
25 were unable to report the 
impact of active smoking on future risk of asthma exacerbation 
as no active smokers were identified in their ‘improved from 
very poorly controlled asthma’ cohort at baseline. Sullivan et 
al.
22 and Peters et al.
13 did not report smoking status. For the 
study reported by O’Connor et al.,
16 the PharMetrics database 
did not hold smoking information. In a questionnaire study, 
Clatworthy et al.,
31 reported that poor asthma control was asso-
ciated with self-reported smoking.
Obesity
High body mass index (BMI) has been shown to be associated 
with both increased incidence of asthma and increased asthma 
severity.
53-55 In terms of asthma control, Barros et al.
56 and Hasel-
korn et al.
57 reported that asthma control is significantly worse 
in patients with a high body mass index. Furthermore, Hasel-
korn et al.
57 reported that patients who gained at least 5 lb (2.27 
kg) or more during the 12 month study period had significantly 
poorer asthma control, worse quality of life and more acute 
courses of oral corticosteroids than patients who had either 
maintained their weight or lost at least 5 lbs (2.27 kg), suggest-
ing that weight gain maybe a causal factor for poor asthma con-
trol. However in terms of future risk of exacerbations, using the 
TENOR study database, both Haselkorn et al.
57 and Sullivan et 
al.
22 reported no association between obesity (defined as a BMI 
≥30) and future risk of asthma exacerbation, although neither 
studies reported whether further stratification into obese, very 
obese or morbidly obese categories was undertaken possibly 
due to small patient numbers. Lavoie et al.
58 reported that high-
er BMI was associated with worse asthma control and quality 
of life, but in contrast to the above studies, after controlling for 
age and gender, they found no association between BMI and 
asthma severity. However, this discrepancy may be due to a se-
lection bias, as all patients participating in the Lavoie et al. were 
recruited from a hospital based asthma clinic and would there-
fore be expected to have moderate to severe asthma. Studies of 
larger patient numbers are required to explore the interaction 
of obesity and future risk of asthma exacerbation. 
Limitations of studies to date
Many of the studies we have reported here have limitations. In 
terms of questionnaire studies, these studies are limited by the 
common issues surrounding questionnaire use: skewed demo-
graphics and inconsistent response rates. Peters et al.
13 report-
ed that of the 62% of 13,964 patients surveyed using the ATAQ, 
only 5,172 were eligible for the study. In contrast, Lai et al.
59 
used an interviewer technique to obtain patient reported ques-
tionnaire data in which prospective participants were ap-
proached either by door-to-door recruitment, street intercep-
tion or peer referral. However, this high cost, high intensity ap-
proach is not practical in routine primary care. Sullivan et al.
22 
utilised TENOR database in which detailed phenotypic data, 
including exacerbations, treatment and laboratory measures of 
patients with severe or difficult to treat asthma were recorded 
on a 6 monthly basis.
17 This prospective database is arguably 
the nearest to capturing of data as part of routine care, but is 
limited by 1) its short duration: 2001 to 2004; 2) possible selec-
tion bias in that only patients with severe or difficult to treat 
asthma were recruited and those without access to healthcare 
were ineligible, and 3) potential recall bias as healthcare utilisa-
tion data was patient reported and not verified with adminis-
trative claims data.
Many studies have utilised managed care claims and health 
plan enrolment databases.
16,52,60 As O’Connor et al.
16 describes, 
these are limited by potential selection bias inherent to claims 
databases. As continuous members of a healthcare plan, these 
patients are more likely to have been in continuous employment, 
compared to the average population. Also symptom, spirome-
try, controller therapy adherence, socioeconomic status and Control and Future Risk in Asthma Management
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race/ethnicity data are unavailable in these databases making 
analyses beyond asthma severity, and disease control using ex-
acerbations and SABA usage very difficult, if not impossible. 
Further improvements in the understanding of asthma con-
trol and the prediction of future risk will require the use of high-
ly descriptive routine primary care databases complemented 
by patient reported questionnaire data. These databases should 
ideally have a large enough population to allow for identifica-
tion of possible sub-groups of patients at risk of exacerbation, 
but also have extensive data to facilitate high quality, meaning-
ful research. We await the results of these studies.
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